107-99-3

Basic information

• Product Name: 2-Chloroethyldimethylamine
• Synonyms: N-(2-Chloroethyl)dimethylamine;2-Chloroethyldimethylamine;Ethanamine, 2-chloro-N,N-dimethyl-;beta-(Dimethylamino)ethyl chloride;N,N-DIMETHYL-BETA-CHLOROETHYLAMINE;DIMETHYL2-CHLOROETHYLAMINE;N-(2-Chloroethyl)-N,N-dimethylamine;1-Chloro-2-(dimethylamino)ethane
• CAS NO: 107-99-3
• Molecular Formula: C₄H₁₀ClN
• Molecular Weight: 107.5819
• EINECS: 203-540-7
• Mol File: 107-99-3.mol
• Article Data: 18

Chemical Properties

• Boiling Point: 160.72°C (rough estimate)
• Flash Point: -11.234 °C
• Appearance: /
• Density: 0.9903 (rough estimate)
• Vapor Pressure: 214mmHg at 25°C
• Refractive Index: 1.5320 (estimate)
• PKA: 8.40±0.28(Predicted)
• CAS DataBase Reference: 2-Chloroethyldimethylamine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Chloroethyldimethylamine(107-99-3)
• EPA Substance Registry System: 2-Chloroethyldimethylamine(107-99-3)

Safety Data

• Hazardous Substances Data: 107-99-3(Hazardous Substances Data)

Usage

Definition

ChEBI: A tertiary amino compound consisting of one 2-chloroethyl and two methyl groups covalently bound to a nitrogen atom.

Safety Profile

Poison by an unspecified route. A systemic irritant. Mutation data reported. When heated to decomposition it emits highly toxic fumes of Cland NOx.

Carcinogenicity

No studies by common exposure routes have been conducted. In addition, dimethyl(b-chloroethyl) amine (and its hydrochloride salt) has not been evaluated by the IARC for carcinogenic potential.

InChI:InChI=1/C4H10ClN/c1-6(2)4-3-5/h3-4H2,1-2H3

Upstream product

• 4584-46-7 (2-chloroethyl)dimethylamine hydrochloride 
• 1429034-73-0 2-hydroxy-N-((7-methoxy-2-oxo-2H-chromen-4-yl)methyl)-N,N-dimethylethanaminium 
• 23950-06-3 (-)-α-codeimethine 
• 108-01-0 2-(N,N-dimethylamino)ethanol 

Downstream Products

• 86178-63-4 maleic acid bis-(2-dimethylamino-ethyl ester) 
• 19249-04-8 bis-dimethylaminoethylsuccinate 
• 116382-99-1 bis(2-dimethylaminoethyl)phthalate 
• 114492-73-8 dimethyl-[2-(5-phenyl-tetrazol-2-yl)-ethyl]-amine 
• 519-30-2 7-(2-dimethylamino-ethyl)-1,3-dimethyl-3,7-dihydro-purine-2,6-dione 
• 531-06-6 Methaferylene 
• 91-80-5 methapyrilene 
• 101117-32-2 N-benzyl-N',N'-dimethyl-N-thiazol-2-yl-ethylenediamine 
• 97020-28-5 1-[2-(2-dimethylamino-ethoxy)-phenyl]-2,5-dimethyl-pyrrole 
• 67465-69-4 10-(2-Dimethylamino-aethyl)-4-aza-phenothiazin 
• 365-77-5 N-(4-fluoro-benzyl)-N',N'-dimethyl-N-pyrimidin-2-yl-ethylenediamine 
• 3569-35-5 solamin 
• 100058-25-1 dimethyl-{2-[5-(4-nitro-phenyl)-tetrazol-2-yl]-ethyl}-amine 
• 15182-06-6 2-(2-N,N-dimethylamino)ethoxybenzaldehyde 

Relevant articles and documents

Direct subphthalocyanine conjugation to bombesin: Vs. indirect conjugation to its lipidic nanocarrier

Bombesin (BBN) was covalently bound to graftable subphthalocyanine (SubPc) or to a cholesterol derivative, a component of a liposome that encapsulates non-graftable SubPc. The latter bioconjugation approach was suitable to address the stability of SubPc and was achieved by copper-free click-chemistry on the outer-face of the liposome. Liposomes were purified (FPLC) and then analyzed in size (outer diameter about 60 nm measured by DLS). In vitro binding studies allowed to determine the IC50 13.9 nM for one component of the liposome, cholesterol, conjugated to BBN. Hence, azido- (or alkynyl-) liposomes give fluorophores with no reactive functional group available on their backbone a second chance to be (indirectly) bioconjugated (with bombesin).

-

-

Isoflavone amide type derivative, preparation method and medical application thereof

The invention relates to the field of medicinal chemistry, and relates to an isoflavone amide type derivative, a preparation method and a medical application thereof, in particular to an isoflavone amide type derivative with the general formula (I), a preparation method thereof, medicine compositions including the isoflavone amide type derivative and a medical application thereof, especially an application of the isoflavone amide type derivative as a medicine for preventing or curing hyperlipemia, obesity or type II diabetes. The general formula (I) is shown in the description.

Design, Synthesis, and Biological Evaluation of Scutellarein Derivatives Based on Scutellarin Metabolic Mechanism in Vivo

Three series of scutellarein derivatives have been designed and synthesized based on metabolic mechanism of scutellarin (1) in vivo. Their thrombin inhibition activities were tested through the analyzation of prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT), and fibrinogen (FIB). The antioxidant activities of these target products were assessed by 1,1-diphenyl-2-picrylhydrazyl radical (DPPH) assay and the ability to protect PC12 cells against H2O2-induced cytotoxicity, and their solubilities were evaluated by ultraviolet (UV) spectrophotometer. The results showed that the two isopropyl groups substituted derivative (18c) demonstrated stronger anticoagulant activity, better water solubility, and good antioxidant activity compared with scutellarein (2), which warrants further development of 18c as a promising agent for ischemic cerebrovascular disease treatment. Three series of scutellarein derivatives have been designed and synthesized based on metabolic mechanism of scutellarin (1) in vivo. The results of the biological evaluation showed that the two isopropyl groups substituted derivative (18c) demonstrated stronger anticoagulant activity, better water solubility, and good antioxidant activity compared with scutellarein (2), which warrants further development of 18c as a promising agent for ischemic cerebrovascular disease treatment.